Physician profile
Christopher Jude
NPI 1699158246
$655.73
in general payments reported to CMS, 2019-2025
15 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.06 · 2022: $223 · 2023: $228 · 2024: $68.67 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.65 | 2022-2025 | |
| Novo Nordisk INC | $76.82 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $76.43 | 2023-2024 | Mounjaro, Zepbound |
| Uswm, LLC | $63.28 | 2023 | Lucemyra, Zimhi |
| Indivior INC. | $60.75 | 2022 | |
| Boston Scientific Corporation | $41.11 | 2022 | |
| Hologic Sales and Service, LLC | $37.80 | 2023 | Aptima |
| Alkermes, INC. | $37.71 | 2021-2022 | |
| Astellas Pharma US INC | $35.01 | 2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $28.74 | 2022 | |
| Abbott Laboratories | $24.46 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2022 | |
| Pfizer INC. | $14.53 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.37 | 2024 | Caplyta |
| Exact Sciences Corporation | $13.53 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.